Cargando…

Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1

INTRODUCTION: Hereditary Tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Current treatment consists of 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and a tyrosine and phenylalanine restricted diet. Recently, neuropsychol...

Descripción completa

Detalles Bibliográficos
Autores principales: van Ginkel, Willem G., van Vliet, Danique, Burgerhof, Johannes G. M., de Blaauw, Pim, Rubio Gozalbo, M. Estela, Heiner-Fokkema, M. Rebecca, van Spronsen, Francjan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614617/
https://www.ncbi.nlm.nih.gov/pubmed/28949985
http://dx.doi.org/10.1371/journal.pone.0185342
_version_ 1783266430534287360
author van Ginkel, Willem G.
van Vliet, Danique
Burgerhof, Johannes G. M.
de Blaauw, Pim
Rubio Gozalbo, M. Estela
Heiner-Fokkema, M. Rebecca
van Spronsen, Francjan J.
author_facet van Ginkel, Willem G.
van Vliet, Danique
Burgerhof, Johannes G. M.
de Blaauw, Pim
Rubio Gozalbo, M. Estela
Heiner-Fokkema, M. Rebecca
van Spronsen, Francjan J.
author_sort van Ginkel, Willem G.
collection PubMed
description INTRODUCTION: Hereditary Tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Current treatment consists of 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and a tyrosine and phenylalanine restricted diet. Recently, neuropsychological deficits have been seen in HT1 patients. These deficits are possibly associated with low blood phenylalanine concentrations and/or high blood tyrosine concentrations. Therefore, the aim of the present study was threefold. Firstly, we aimed to calculate how the plasma amino acid profile in HT1 patients may influence the presumptive brain influx of all large neutral amino acids (LNAA). Secondly, we aimed to investigate the effect of phenylalanine supplementation on presumptive brain phenylalanine and tyrosine influx. Thirdly, we aimed to theoretically determine minimal target plasma phenylalanine concentrations in HT1 patient to ensure adequate presumptive brain phenylalanine influx. METHODS: Data of plasma LNAA concentrations were obtained. In total, 239 samples of 9 HT1 children, treated with NTBC, diet, and partly with phenylalanine supplementation were collected together with 596 samples of independent control children. Presumptive brain influx of all LNAA was calculated, using Michaelis-Menten parameters (K(m)) and V(max)-values obtained from earlier articles. RESULTS: In HT1 patients, plasma concentrations and presumptive brain influx of tyrosine were higher. However, plasma and especially brain influx of phenylalanine were lower in HT1 patients. Phenylalanine supplementation did not only tend to increase plasma phenylalanine concentrations, but also presumptive brain phenylalanine influx, despite increased plasma tyrosine concentrations. However, to ensure sufficient brain phenylalanine influx in HT1 patients, minimal plasma phenylalanine concentrations may need to be higher than considered thus far. CONCLUSION: This study clearly suggests a role for disturbed brain LNAA biochemistry, which is not well reflected by plasma LNAA concentrations. This could play a role in the pathophysiology of the neuropsychological impairments in HT1 patients and may have therapeutic implications.
format Online
Article
Text
id pubmed-5614617
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56146172017-10-09 Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 van Ginkel, Willem G. van Vliet, Danique Burgerhof, Johannes G. M. de Blaauw, Pim Rubio Gozalbo, M. Estela Heiner-Fokkema, M. Rebecca van Spronsen, Francjan J. PLoS One Research Article INTRODUCTION: Hereditary Tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Current treatment consists of 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and a tyrosine and phenylalanine restricted diet. Recently, neuropsychological deficits have been seen in HT1 patients. These deficits are possibly associated with low blood phenylalanine concentrations and/or high blood tyrosine concentrations. Therefore, the aim of the present study was threefold. Firstly, we aimed to calculate how the plasma amino acid profile in HT1 patients may influence the presumptive brain influx of all large neutral amino acids (LNAA). Secondly, we aimed to investigate the effect of phenylalanine supplementation on presumptive brain phenylalanine and tyrosine influx. Thirdly, we aimed to theoretically determine minimal target plasma phenylalanine concentrations in HT1 patient to ensure adequate presumptive brain phenylalanine influx. METHODS: Data of plasma LNAA concentrations were obtained. In total, 239 samples of 9 HT1 children, treated with NTBC, diet, and partly with phenylalanine supplementation were collected together with 596 samples of independent control children. Presumptive brain influx of all LNAA was calculated, using Michaelis-Menten parameters (K(m)) and V(max)-values obtained from earlier articles. RESULTS: In HT1 patients, plasma concentrations and presumptive brain influx of tyrosine were higher. However, plasma and especially brain influx of phenylalanine were lower in HT1 patients. Phenylalanine supplementation did not only tend to increase plasma phenylalanine concentrations, but also presumptive brain phenylalanine influx, despite increased plasma tyrosine concentrations. However, to ensure sufficient brain phenylalanine influx in HT1 patients, minimal plasma phenylalanine concentrations may need to be higher than considered thus far. CONCLUSION: This study clearly suggests a role for disturbed brain LNAA biochemistry, which is not well reflected by plasma LNAA concentrations. This could play a role in the pathophysiology of the neuropsychological impairments in HT1 patients and may have therapeutic implications. Public Library of Science 2017-09-26 /pmc/articles/PMC5614617/ /pubmed/28949985 http://dx.doi.org/10.1371/journal.pone.0185342 Text en © 2017 van Ginkel et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
van Ginkel, Willem G.
van Vliet, Danique
Burgerhof, Johannes G. M.
de Blaauw, Pim
Rubio Gozalbo, M. Estela
Heiner-Fokkema, M. Rebecca
van Spronsen, Francjan J.
Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
title Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
title_full Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
title_fullStr Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
title_full_unstemmed Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
title_short Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
title_sort presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with tyrosinemia type 1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614617/
https://www.ncbi.nlm.nih.gov/pubmed/28949985
http://dx.doi.org/10.1371/journal.pone.0185342
work_keys_str_mv AT vanginkelwillemg presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1
AT vanvlietdanique presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1
AT burgerhofjohannesgm presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1
AT deblaauwpim presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1
AT rubiogozalbomestela presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1
AT heinerfokkemamrebecca presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1
AT vanspronsenfrancjanj presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1